These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 20231400)
21. Raft localization of CXCR4 is primarily required for X4-tropic human immunodeficiency virus type 1 infection. Kamiyama H; Yoshii H; Tanaka Y; Sato H; Yamamoto N; Kubo Y Virology; 2009 Mar; 386(1):23-31. PubMed ID: 19178925 [TBL] [Abstract][Full Text] [Related]
22. Safe use of the CXCR4 inhibitor ALX40-4C in humans. Doranz BJ; Filion LG; Diaz-Mitoma F; Sitar DS; Sahai J; Baribaud F; Orsini MJ; Benovic JL; Cameron W; Doms RW AIDS Res Hum Retroviruses; 2001 Apr; 17(6):475-86. PubMed ID: 11350661 [TBL] [Abstract][Full Text] [Related]
23. CXCR4-dependent infection of CD8+, but not CD4+, lymphocytes by a primary human immunodeficiency virus type 1 isolate. Zerhouni B; Nelson JA; Saha K J Virol; 2004 Nov; 78(22):12288-96. PubMed ID: 15507616 [TBL] [Abstract][Full Text] [Related]
24. Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses. Okuma K; Tanaka R; Ogura T; Ito M; Kumakura S; Yanaka M; Nishizawa M; Sugiura W; Yamamoto N; Tanaka Y J Infect Dis; 2008 Jan; 197(1):134-41. PubMed ID: 18171296 [TBL] [Abstract][Full Text] [Related]
25. Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. Ribeiro RM; Hazenberg MD; Perelson AS; Davenport MP J Virol; 2006 Jan; 80(2):802-9. PubMed ID: 16378982 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of tyrosine kinase activation blocks the down-regulation of CXC chemokine receptor 4 by HIV-1 gp120 in CD4+ T cells. Su SB; Gong W; Grimm M; Utsunomiya I; Sargeant R; Oppenheim JJ; Ming Wang J J Immunol; 1999 Jun; 162(12):7128-32. PubMed ID: 10358157 [TBL] [Abstract][Full Text] [Related]
27. Identification of HIV-1 epitopes that induce the synthesis of a R5 HIV-1 suppression factor by human CD4+ T cells isolated from HIV-1 immunized hu-PBL SCID mice. Yoshida A; Tanaka R; Kodama A; Yamamoto N; Ansari AA; Tanaka Y Clin Dev Immunol; 2005 Dec; 12(4):235-42. PubMed ID: 16584108 [TBL] [Abstract][Full Text] [Related]
28. Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells. Xiao X; Kinter A; Broder CC; Dimitrov DS Exp Mol Pathol; 2000 Jun; 68(3):133-8. PubMed ID: 10816381 [TBL] [Abstract][Full Text] [Related]
29. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Princen K; Schols D Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254 [TBL] [Abstract][Full Text] [Related]
30. [Human immunodeficiency virus (HIV) co-receptors expression in mononuclear leucocytes (ML) of HIV+ patients]. Belmonte L; de Elizalde de Bracco MM; Ruibal-Ares B Medicina (B Aires); 2001; 61(5 Pt 2):670-2. PubMed ID: 12058586 [TBL] [Abstract][Full Text] [Related]
31. Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. Secchiero P; Zella D; Capitani S; Gallo RC; Zauli G J Immunol; 1999 Feb; 162(4):2427-31. PubMed ID: 9973525 [TBL] [Abstract][Full Text] [Related]
32. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065 [TBL] [Abstract][Full Text] [Related]
33. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. Biancotto A; Grivel JC; Gondois-Rey F; Bettendroffer L; Vigne R; Brown S; Margolis LB; Hirsch I J Virol; 2004 Oct; 78(19):10507-15. PubMed ID: 15367617 [TBL] [Abstract][Full Text] [Related]
34. Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review). Lehrer S World Acad Sci J; 2020 May; 2(3):. PubMed ID: 32313883 [TBL] [Abstract][Full Text] [Related]
35. Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat. Keogan S; Passic S; Krebs FC Int J Pept; 2012; 2012():349427. PubMed ID: 22319541 [TBL] [Abstract][Full Text] [Related]
36. Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Pirrone V; Passic S; Wigdahl B; Krebs FC Virol J; 2012 Jan; 9():33. PubMed ID: 22281044 [TBL] [Abstract][Full Text] [Related]
37. Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model. Lozenski K; Kish-Catalone T; Pirrone V; Rando RF; Labib M; Wigdahl B; Krebs FC J Biomed Biotechnol; 2011; 2011():941061. PubMed ID: 22131821 [TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Passic SR; Ferguson ML; Catalone BJ; Kish-Catalone T; Kholodovych V; Zhu W; Welsh W; Rando R; Howett MK; Wigdahl B; Labib M; Krebs FC Biomed Pharmacother; 2010 Dec; 64(10):723-32. PubMed ID: 21106331 [TBL] [Abstract][Full Text] [Related]
39. Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4. Wilkinson RA; Pincus SH; Shepard JB; Walton SK; Bergin EP; Labib M; Teintze M Antimicrob Agents Chemother; 2011 Jan; 55(1):255-63. PubMed ID: 20937786 [TBL] [Abstract][Full Text] [Related]